KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915.

Georgina V Long, Hao Tang, Keyur Desai, Sheen Wang, Michele Del Vecchio, James Larkin, Corey Ritchings, Shu-Pang Huang, Jonathan Baden, David Balli, Han Chang, Gina Fusaro, Daniel Tenney, Sonia Dolfi, Jeffrey Weber

J Immunother Cancer 13(7) e012034

PMID40645660
PMCIDPMC12248205
DOI10.1136/jitc-2025-012034
发表日期2025-07-11
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: CheckMate 915 (NCT03068455) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that correlate with benefit from adjuvant immunotherapy. PATIENTS AND METHODS: 1,844 patients received nivolumab 480 mg every 4 weeks or nivolumab 240 mg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks. Tumor and peripheral biomarkers were evaluated, including tumor-informed circulating tumor DNA (ctDNA) at postresection baseline and on-treatment, for their association with recurrence-free survival and distant metastases-free survival. RESULTS: Biomarker analyses were conducted in 60-96% of the intention-to-treat population. ctDNA positivity at baseline (seen in 16.2% of patients) and on-treatment was associated with higher risk of recurrence than ctDNA negativity (HR, 1.97; 95% CI, 1.57 to 2.46), with a high specificity (87%) and modest sensitivity (39%). ctDNA status, tumor mutational burden (TMB) status (TMB < or ≥350 mutations/tumor) and interferon gamma-RNA signature score (< or ≥median) evaluated together, as well as ctDNA status with tumor CD8 or cell programmed death ligand 1 expression, were more predictive of survival than ctDNA alone. Tumor bulk RNA-seq expression patterns identified gene expression at baseline associated with recurrence. CONCLUSIONS: This study represents the largest assessment of ctDNA and other baseline tumor and peripheral biomarkers for predicting recurrence-free survival in patients with resected melanoma receiving adjuvant immunotherapy. ctDNA alone and in combination with more established biomarkers predicted recurrence-free and distant metastasis-free survival and has potential utility for assessing and monitoring the risk of recurrence in patients with resected melanoma treated with immunotherapy in the adjuvant setting. TRIAL REGISTRATION NUMBER: NCT03068455.

KM 提取结果

3 个 Figure · 11 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

Figure 1. Association of baseline ctDNA positivity with ( A ) RFS and ( B ) DMFS; ( C ) Sensitivity and specificity for predicting recurrence; ( D ) Association of baseline ctDNA positivity with first recurrence in the 1,127-patient ctDNA-evaluable subgroup. For recurrences, data from the first recorded 1,138 recurrences in 343 patients in the ctDNA-evaluable cohort with recurrence were used. The pink circles in figures A and B denote early recurrences and highlight the differences in recurrence rates between the baseline ctDNA groups. a In patients with stage III disease. b,c Sensitivity and specificity for predicting RFS and DMFS at 3 and 24 months are represented. To calculate 3-month RFS sensitivity/specificity, the patients with recurrence after ≤3 months were marked as positives and the remaining patients were marked as negatives. The fraction of ctDNA(+) patients among the positives provided the sensitivity of baseline ctDNA and the fraction of ctDNA(−) patients among the negatives provided the specificity of baseline ctDNA in predicting 3-month recurrence. The sensitivity and specificity for RFS at 24 months, DMFS at 3 months, and DMFS at 24 months were determined in a similar manner. ctDNA, circulating tumor DNA; DMFS, distant metastasis-free survival; IPI, ipilimumab; mo, months; NIVO, nivolumab; RFS, recurrence-free survival; ST, soft tissue.

A

Recurrence-free survival

Figure 1 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme upward reversal曲线 4:off origin start
查看结果
B

Distant metastases-free survival

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 3:extreme jump
查看结果
KM Figure6 个面板

Figure 2

Figure 2. ( A ) Landmark analysis of RFS at any time by baseline ctDNA status ( i ) and week 13 ( ii ) and week 29 ( iii ) by on-treatment ctDNA status. ( B ) Association of combined baseline and on-treatment ctDNA status with RFS. BL, baseline; ctDNA, circulating tumor DNA; RFS, recurrence-free survival; W, week.

A

RFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

RFS

Figure 2 · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_3

RFS

Figure 2 · Panel A_3

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_3 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:frequent upward jumps曲线 2:extreme upward reversal
查看结果
B

RFS

Figure 2 · Panel B

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B_5

RFS

Figure 2 · Panel B_5

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel B_5 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 5:extreme upward reversal
查看结果
B_6

RFS

Figure 2 · Panel B_6

quality_warning 待 EXE 对齐 预期 5 条 已提取 1 条

Panel B_6 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 5 条,实际恢复 1 条
查看结果
KM Figure3 个面板

Figure 5

Figure 5. ( A ) Association of ( i ) ctDNA status, ( ii ) TMB and IFNγ-RNA signature score, and ( iii ) combined ctDNA status, TMB, and IFNγ-RNA signature score with RFS in the pooled nivolumab and nivolumab+ipilimumab treatment arms. ( B ) Time-dependent association of ctDNA status and tumor factors with recurrence in patients treated with nivolumab+ipilimumab. ( i ) Receiver operating characteristic curve for baseline ctDNA status for prediction of recurrence across varying time points. ( ii ) Area under the curve (AUC) for predictive value of ctDNA status over time. ( iii ) AUC for predictive value of individual baseline biomarkers, with each curve representing an individual biomarker and its predictive capacity for RFS with time. ( iv ) AUC for predictive value of baseline biomarker combinations. a IFNγ-RNA signature score: samples were considered high if the signature score was ≥ median. b TMB stratified by tertiles for visualization purposes: TMB low (lower two tertiles), <350 mutations; TMB high (upper tertile), ≥350 mutations. ctDNA, circulating tumor DNA; GEP, gene expression profile; H, high; IFNγ-RNA signature, interferon gamma RNA signature; IHC, immunohistochemistry; L, low; PD-L1, programmed death ligand 1; RFS, recurrence-free survival; t, time; TMB, tumor mutational burden.

A

RFS

Figure 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

RFS

Figure 5 · Panel A_2

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A_2 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_3

RFS

Figure 5 · Panel A_3

quality_warning 待 EXE 对齐 预期 8 条 已提取 6 条

Panel A_3 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 8 条,实际恢复 6 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 3Figure 3. Association of ctDNA status at ( A ) baseline, ( B ) baseline and week 13, and ( C ) baseline and week 29 with baseline; ( i ) CD8+ T cell infiltration, ( ii ) IFNγ-RNA signature score, ( iii ) tumor cell PD-L1 expression, and ( iv ) TMB. Nominal p values were estimated by the Wilcoxon test, not adjusted for multiplicity. Comparisons that were non-significant and not trending towards significance (p>0.1) were labeled as ns. BL, baseline; ctDNA, circulating tumor DNA; IFNγ, interferon gamma; ns, not significant; PD-L1, programmed death ligand 1; TMB, tumor mutational burden; W, week.
非 KM Figure
Figure 4Figure 4. Forest plot showing associations with prolonged RFS for biomarkers, patient and tumor characteristics in the nivolumab and nivolumab+ipilimumab, and combined treatment arms. a HR is a higher level of biomarker over lower level of biomarker from the Cox proportional hazards model, which comprises three covariates: the treatment arm, the continuous biomarker, and their interaction. b Higher versus lower refers to evaluating biomarkers as continuous variables; higher level of the biomarker is the 75th percentile value of the biomarker in the overall population, and lower level of the biomarker is the 25th percentile value of the biomarker in the overall population. ctDNA, circulating tumor DNA; GEP, gene expression profile; IFNγ, interferon gamma; IHC, immunohistochemistry; IPI, ipilimumab; NIVO, nivolumab; PD-L1, programmed death ligand 1; RFS, recurrence-free survival; TMB, tumor mutational burden.
非 KM Figure